retatrutide nonalcoholic steatohepatitis trial Liraglutide safety and efficacy in patients with non-alcoholic (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study retatrutide nonalcoholic fatty liver disease

doi: 10.4103/0970-9290.38932 70 RambhiaPHStojanovIJArbesmanJ

This is software that understands the physiological impact of the drug

Where it comes from and how it is manufactured Bacteriostatic water is not a modern invention, the concept of preserved sterile water with benzyl alcohol has been used in laboratory and pharmaceutical practice for decades

Evidence references ADJUNCT ONE, PMID 27506222 ADJUNCT TWO, PMID 27493132 ADJUST T1D, PMID 40550013 Semaglutide crossover study, PMID 39794615 Tirzepatide observational data (Shah 2024), PMC11571402 Shah discontinuation post-hoc (ADJUNCT I/II), PMID 39717993 Shah 2025, GLP-1RA / tirzepatide in T1D with severe early (genetic) obesity ( JDST ) Insulin titration paper, PMID 39829697 Adjunct therapy review, PMID 40618954 Bone health review, PMC8118128 Weight loss and bone, PMID 38916894 Consensus and guidelines: ADA Standards 2025, PMID 39651989 ISPAD 2024, PMID 39657603 GLP-1 AID consensus, PMID 39517127 Related reading on GNL This Episode 17 conversation was the inspiration for the four-part Adjunctive Therapies guide built on top of the April 2026 evidence update